Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 2974-2977

  Restrepo, M I ^a   Velez, J A ^a,c   McElmeel, M L ^a   Whitney, C G ^b   Jorgensen, J H ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c UNIVERSIDAD CES   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CEFOTAXIME; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DAPTOMYCIN PLUS CALCIUM; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG MECHANISM; DRUG SCREENING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SHEEP; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CALCIUM; CULTURE MEDIA; DAPTOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0042924377     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.2974-2977.2003     Document Type: Article

References (29)

1. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
2. Appelbaum, P. C., S. K. Spangler, E. Crotty, and M. R. Jacobs. 1989. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones. J. Antimicrob. Chemother. 23:509-516.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
4. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File, Jr., D. M. Musher, and M. J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.
5. Butler, J. C., J. Hofmann, M. S. Cetron, J. A. Elliott, R. F. Facklam, and R. F. Breiman. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal surveillance system. J. Infect. Dis. 174:986-993.
6. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
7. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. S. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
8. Doern, G. V., A. B. Brueggemann, H. Huynh, E. Wingert, and P. Rhomberg. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis. 5:757-765.
9. Feikin, D. R., A. Schuchat, M. Kolczak, N. L. Barrett, L. H. Harrison, L. Lefkowitz, A. McGeer, M. M. Farley, D. J. Vugia, C. Lexau, K. R. Stefonek, J. E. Patterson, and J. H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-229.
10. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2001. Evaluation of daptomycin susceptibility testing by E test and the effect of different batches of media. J. Antimicrob. Chemother. 48:557-561.
11. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2003. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezoiid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob. Agents Chemother. 47:337-341.
12. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716.
13. Heffelfinger, J. D., S. F. Dowell, J. H. Jorgensen, K. P. Klugman, L. R. Mabry, D. M. Musher, J. E. Plouffe, A. Rakowsky, A. Schuchat, and C. G. Whitney. 2000. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160:1399-1408.
14. Ho, P. L., T. L. Que, D. N. Tsang, T. K. Ng, K. H. Chow, and W. H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43:1310-1313.
15. Ho, P. L., W. S. Tse, K. W. Tsang, T. K. Kwok, T. K. Ng, V. C. C. Cheng, and R. M. T. Chan. 2001. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. 32:701-707.
16. Hyde, T. B., K. Gay, D. S. Stephens, D. J. Vugia, M. Pass, S. Johnson, N. L. Barrett, W. Schaffner, P. R. Cieslak, P. S. Maupin, E. R. Zell, J. H. Jorgensen, R. R. Facklam, and C. G. Whitney. 2001. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286:1857-1862.
17. Jorgensen, J. H., L. A. Maher, and J. S. Redding. 1987. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria. Eur. J. Clin. Microbiol. 6:91-96.
18. Kelley, M. A., D. M. Weber, P. Gilligan, and M. S. Cohen. 2000. Break-through pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31:1008-1011.
19. Lakey, J. H., and M. Ptak. 1988. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY 146032 and phospholipid membranes. Biochemistry 27:4639-4645.
20. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, Pa.
21. NCCLS. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8. NCCLS, Wayne, Pa.
22. NCCLS. 2003. Performance standards for antimicrobial susceptibility testing. Supplement M100-S13. NCCLS, Wayne, Pa.
23. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
24. Rodriguez-Tudela, J. L., F. Lopez de Felipe, J. V. Martinez-Suarez, and A. Fenoll. 1992. Comparative in-vitro activity of four peptide antibiotics against penicillin-resistant Streptococcus pneumoniae isolated from cerebrospinal fluid (CSF). J. Antimicrob. Chemother. 29:299-302.
25. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
26. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.
27. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
28. Thornsberry, C., P. T. Ogilvie, H. P. Holley, Jr., and D. F. Sahm. 1999. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob. Agents Chemother. 43:2612-2623.
29. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen, and A. Schuchat. 2001. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.